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Introduction: Metastasis is the main cause of breast cancer morbidity and mortality. Processes that allow for
tumor cell migration and invasion are important therapeutic targets. Here we demonstrate that receptor-interacting
protein kinase 2 (RIP2), a kinase known to be involved in inflammatory processes, also has novel roles in cancer cell
migration and invasion.
Methods: A total of six breast cancer expression databases, including The Cancer Genome Atlas, were assessed for
RIP2 expression among various clinical subtypes and its role as a prognostic biomarker. mRNA fluorescence in situ
hybridization (FISH) for RIP2 was performed on 17 stage III breast cancers to determine if there was a correlation
between RIP2 expression and lymph node involvement. RNA-interference was used to knock-down RIP2 expression
in MDA-MB-231, Htb126, SUM149PT, MCF7, T47D, and HCC1428 cells. Cell migration and invasion were measured
in vitro by scratch/wound healing and transwell migration assays. A xenograft mouse model was used to assess
tumor growth and chemosensitivity to docetaxel in vivo in MDA-MB-231 cells with and without RIP2 small hairpin
RNA knockdown. Western blot and immunofluorescence imaging were used to evaluate protein expressions.
Results: Interrogation of expression databases showed that RIP2 expression is significantly over-expressed in
triple-negative breast cancers (TNBC: estrogen-receptor (ER) negative, progesterone-receptor (PR) negative, Her2/
neu- (Her2) negative), compared to other clinical subtypes. High RIP2 expression correlates with worse
progression-free survival using a combined breast cancer expression array dataset consisting of 946 patients.
Multivariate analysis shows RIP2 as an independent prognostic biomarker. Knock-down of RIP2 significantly
decreases migration in both scratch/wound healing and transwell migration assays in MDA-MB-231, Htb126,
SUM149PT, MCF7, and T47D cells and is correlated with decreased Nuclear Factor-kappaB and c-Jun N-terminal
kinase (JNK) activation. Finally, RIP2 knock-down leads to increased sensitivity to docetaxel and decreased tumor
mass and lung metastases in a xenograft mouse model.
Conclusion: These results highlight RIP2 as a pro-metastasis kinase in patients with advanced breast cancer.
These results also illustrate a novel role for this kinase in addition to its known role in inflammation, and suggest
that targeting RIP2 may improve outcomes in advanced breast cancer patients, in which it is overexpressed.* Correspondence: Jerry.Shay@utsouthwestern.edu
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Receptor-interacting protein kinase 2 (RIP2, also known
as RIPK2, RICK and CARDIAK) is a serine/threonine/
tyrosine kinase with a carboxy-terminal caspase activa-
tion and recruitment domain (CARD) known for its role
in inflammation and immunity [1-3]. RIP2 association
with the TNF receptor (TNFR) causes direct activation
of NF-kappa B and induction of apoptosis [4-6]. We had
previously demonstrated an unrecognized role of RIP2
in breast cancer and as a potential chemosensitizer [7].
Here we investigate the functional significance of RIP2
expression in breast cancer.
RIP2 has been associated with activation of the NF-kappa
B, c-Jun N-terminal kinase (JNK), extracellular signal-regu-
lated kinase (ERK), and mitogen-activated protein kinase
(p-38) pathways [3,6,8,9]. Involvement in metastasis has
been implicated in all of these pathways. NF-kappa B has
been shown to be important for promoting migration and
metastasis [10] and upregulating the expression of matrix
metalloproteinases, urokinase-type plasminogen activator,
and cytokines in highly metastatic cancer cell lines [11-13].
In contrast, although JNK is important in inflammation,
proliferation, and apoptosis, it also regulates cell migration
by maintaining the labile adhesions required for rapid cell
migration [14,15]. In addition, both ERK [16] and p-38 [17]
have been shown to be involved in tumor cell migration.
In this study, we found that RIP2 overexpression is
most significant in triple-negative breast cancer (TNBC)
and that RIP2 expression correlates with worse progres-
sion-free survival (PFS). RIP2 is an independent prognos-
tic biomarker in multivariate analysis. mRNA fluorescence
in situ hybridization (FISH) analysis of patients with
locally advanced breast cancer and extensive lymph node
metastases demonstrates increased RIP2 expression com-
pared to patients with limited lymph node metastasis.
When RIP2 expression is knocked down in MDA-MB-
231, Htb126, SUM149PT, MCF7, and T47D breast cancer
cells, there is significantly decreased migration as demon-
strated by functional assays in vitro. Furthermore, RIP2
knockdown decreases tumor cell growth during che-
motherapy in vivo and reduces lung metastases from
MDA-MB-231 xenografts. We found that RIP2 expres-
sion regulates NF-kappa B and JNK activation in breast
cancer cell lines. In addition, PP2, an RIP2 small mol-
ecule chemical inhibitor, decreases JNK activation and
leads to decreased migration in vitro. Together, our
findings demonstrate a novel role for RIP2 as a kinase
involved in the migration of TBNC cells and in selected
estrogen receptor (ER)-positive breast cancer cells.
Methods
Cells and chemicals
MDA-MB-231 and Htb126 cells were cultured in basal
medium supplemented with 10% fetal calf serum andwere originally purchased from American Type Culture
Collection (ATCC, Manassas, VA, USA) and kindly pro-
vided by M White, Department of Cell Biology, University
of Texas Southwestern Medical School, Dallas, TX.
SUM149PT was purchased from Asterand (Detroit, MI,
USA) and grown as per supplier’s instructions. MCF7,
Htb126, and HCC1428 were purchased from ATCC and
grown per supplier’s instructions. PP2 was obtained from
Tocris Bioscience (Bristol, UK) and used at the indicated
concentrations.
Expression array analysis and statistics
The Cancer Genome Atlas (TCGA) breast cancer expres-
sion data and clinical annotations were downloaded from
the TCGA website [18]. Five other publically available
breast cancer expression datasets [19-21] were separately
normalized then pooled for analysis (n = 946) as previ-
ously described [7]. Data were downloaded from GEO
[22] [GSE3494 [19]; GSE6532 [20]; GSE1456 [23];
GSE7390 [24]] and from NKI [25]. These datasets were
chosen for having clinical annotations that include ER sta-
tus, axillary lymph node involvement, PFS and/or overall
survival information. Briefly, probes were mapped using
Entrez identifiers and Human Genome Organization gene
symbols and then averaged for gene-level analysis. Missing
values were imputed using nearest neighbor averaging. All
data analysis was conducted using tools in R/Bioconduc-
tor. Datasets were merged and standardized by scaling the
columns, then the rows, and finally checked using prin-
cipal component analysis (PCA) as previously reported
[7]. Triple-negative samples were predicted from the
annotated ER-negative samples using the subtyping
tool, TNBCtype [26]. Univariate and multivariate Cox
regression with Pearson correlation coefficient was per-
formed using the R survival package version 2.36-14.
Wald test P-values are reported for univariate Cox pro-
portional hazards model; local Wald and overall log-
rank P-values are reported for the multivariate model
using Cox proportional hazards regression model. Sur-
vival curves were evaluated by Kaplan-Meier estimators
with log-rank P-values reported. The median expression
of RIP2 was used to split each dataset into two cohorts to
examine expression patterns in samples that belong to the
four clinical subtypes of breast cancer. P-values within
boxplots were determined using the Welch two-sample
t-test.
Xenografts and human tissues
We injected 2,000,000 MDA-MB-231 cells into each
dorsal flank subcutaneously in 6-week old NOD/SCID
mice. For primary tumor growth experiments, sh-control
and shRIP2 cells were injected into contralateral flanks.
For lung metastasis studies, either sh-control or shRIP2
cells were injected into each mouse. Four weekly IP
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ing at 7 days after xenograft placement. Tumor volumes
were measured weekly and were calculated as:
Width2  Length mm2=2:
At 10 weeks after xenograft placement, primary tumors
and lungs were harvested and fixed in formalin for paraf-
fin embedding. A mid-sagittal cut was made to each lung.
Two sections per lung (200 microns apart) were mounted
to glass slides and stained with hematoxylin and eosin
(H&E) (Thermo Scientific, Kalamazoo, MI, USA), and
imaged with Zeiss Axioskop2Plus (Thornwood, NY, USA).
All animal work was approved by University of Texas
Southwestern (UTSW) Institutional Animal Care and Use
Committee (IACUC) and performed per institutional
guidelines. De-identified primary human breast tumors
were obtained from the UTSW Tissue Repository where
tissues were originally obtained with patient consent
and used with approval from UTSW Institutional Review
Board.
Plasmids and transfections
pGIPZ RIP2 lentiviral shRNA was obtained from Open
Biosystems (clone V2LHS_17021, Thermo Scientific, Inc.
Pittsburgh, PA, USA). siRNAs designated as #D and #J
were obtained from Dharmacon (clones D-003602-01-
0005 and J-003602-09-0005, respectively from Thermo
Scientific) and used with Lipofectamine RNAi Max
reagent (Invitrogen, Grand Island, NY, USA) as per
manufacturer’s protocol. pcDNA4 Omni-tagged RIP2
was kindly provided by D Abbott [27] (Department of
Pathology, Case Western Reserve University, Cleveland,
OH, USA) [28]. cDNA transfections were performed
with Lipofectamine LTX reagent (Invitrogen) as per
manufacturer’s protocol.
Viral transductions and stable selections
For lentivirus production, 1 μg of pGIPZ-shRNA plasmid
together with 1 μg of helper plasmids (0.4 μg pMD2G and
0.6 μg psPAX2) were transfected into 293FT cells with
Effectene reagent (Qiagen, Valencia, CA, USA). Viral su-
pernatants were collected 48 hours after transfections and
cleared through a 0.45-μm filter. Cells were infected with
viral supernatants containing 4 μg/mL polybrene (Sigma,
St. Louis, MO) and selected with puromycin for 7 days.
Western blot analysis and immunofluorescence
Total cell lysates were prepared by harvesting cells in
Laemmli SDS reducing buffer. Protein concentrations
were measured using a Pierce BCA protein assay kit
(Thermo Scientific, Rockford, IL, USA), resolved on an
8% to 10% polyacrylamide gel, and transferred to a poly-
vinylidine fluoride membrane. The following antibodiesare from Cell Signaling (Beverly, MA, USA): glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) (2118),
p-JNK (4668), JNK (9258), p-p38 (4511), p38 (8690),
p-NFkappa (3031), NFkappa (8242), p-ERK1/2 (4377),
ERK 1/2(4695), p-RIP2 (4364). RICK (RIP2) antibody
(sc-136059) was from Santa Cruz Biotech (Dallas, TX,
USA). Focal adhesion kinase (FAK) (ab40794) and p-FAK
(ab4803) antibodies were from Abcam (Cambridge, MA).
Detection of peroxidase activity from HRP-conjugated
antibodies was done with SuperSignal West Femto Max-
imum Sensitivity Substrate (Thermo Scientific, Rockford,
IL, USA). Images were captured with the G:BOX F3 with
GeneSys software (SynGene, Frederick, MD). Alexa Fluor
568 anti-rabbit secondary antibody (Invitrogen) was used
for immunofluorescence and images were taken at 100×
with Zeiss Axiovert 200M (Thornwood, NY, USA).
Scratch/wound healing assay and Matrigel™ invasion assays
Cells were grown in normal growth media to monolayer
confluence in 6-well tissue culture plates. They were
then treated with mitomycin C (10 μg/mL) (Sigma, St.
Louis, MO, USA) for 2 hours prior to scratching with
a 1-mL pipette tip. A perpendicular pen mark on the
tissue culture plate was used to mark the place for
repeated imaging with an EVOS microscope (AMG/Life
Technologies, Grand Prairie, TX, USA). For Matrigel™
invasion assays, cells were serum-starved for 16 hours,
then 100,000 cells were seeded in the top chamber, in
serum-free media, of 24-well invasion chambers, 8-μm
pores (BD Biosciences, San Jose, CA, USA) with growth
media in bottom chamber. Cells are allowed to migrate
for 16 hours with processing procedure per manufac-
turer’s protocol. Hoechst 33342 (Sigma, St. Louis, MO,
USA) was used to stain nuclei for imaging at 20× with the
Zeiss Axiovert 200M and quantification with ImageJ
(NIH, Bethesda, MD, USA).
Fluorescence in situ hybridization
Stellaris™ mRNA FISH probes against RIP2, CAL Fluor
Red 610, was obtained from Biosearch Technologies
(Novato, CA, USA) and hybridization performed as per
manufacturer’s protocol. Images were obtained with
Deltavision (Applied Precision, Issaquah, WA, USA) and
quantification was with ImageJ.
Results
RIP2 overexpression correlates with triple-negative status
and poor progression-free survival in breast cancer
We had previously shown that KIF14, a protein-protein
interactor of RIP2 [29], is significantly over-expressed in
triple-negative breast cancer. We examined TCGA [30]
to see if RIP2 overexpression is also more common among
triple-negative primary breast cancers. TBNCs, even
though representing only 15% (71/459) of total cases, have
A B
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Figure 1 Distribution of high- and low- RIP2 expressions (dichotomized at the median) of the Cancer Genome Atlas (A) and public
breast cancer expression array datasets (B) (see Methods) within each designated clinical subtype of breast cancer. Survival curves using
Kaplan-Meier estimators using RIP2 as a biomarker (dichotomized about the median in C and using only top and bottom 30% of all patients in
D for progression-free survival (PFS) with log-rank P-values reported. Red denotes higher expression and black denotes lower expression. HR,
hazard ratio.
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87.3%, left side, ER-/PR-/Her2-) relative to the other clin-
ical subtypes (Figure 1A, middle and right side). We next
tested if high-RIP2 expression is also over-represented in
other datasets. We chose five large, publicly available
breast cancer expression array datasets that have adequate
clinical annotations including ER status, axillary lymph
node involvement, progression-free and/or overall survival
data (n = 946 for PFS and n = 652 for overall survival, see
Methods and as previously described [7]). As Her2 status
is not annotated in these other datasets, we used the
annotated ER-negative samples and obtained predicted
triple-negative status from a validated public software plat-
form TNBCtype [27]. Here, we also found that high-RIP2
expression is over-represented in the (predicted) triple-
negative subgroup compared to others (see Figure 1B).
RIP2 expression correlated to PFS but not overall sur-
vival outcomes analyzed by univariate Cox regression
(P = 1.247e-4 and P = 0.281, respectively). Kaplan-
Meier analysis of PFS when expression values were
dichotomized at the median demonstrated the significant
prognostic value of RIP2 expression (Figure 1C, red line,
high levels of RIP2 versus black, low level of RIP2). The
significance increased when patients in the top versus
the bottom 30% of RIP2 expression were compared
(Figure 1D). As RIP2 was highly correlated with triple-
negative status, we examined this subgroup of patients
(predicted from TNBCtype, n = 119; see Methods) but did
not find that RIP2 expression within the TNBC cohort
correlated with PFS when expression values were dichoto-
mized at the median (P = 0.35, hazard ratio (HR) 0.8, 95%
CI 0.4, 1.3) or when only the top versus bottom 30% of
RIP2 expression were used (P = 0.68, HR 1.3, 95% CI 0.4,
4.1). On the other hand, multivariate analysis using Cox
proportional hazards regression analysis using RIP2
expression and clinical features (triple-negative status,
axillary lymph node involvement, ER status, size, and age)
indicated that RIP2 is an independent prognostic bio-
marker (P = 0.0033, HR 1.43, 95% CI 1.10, 1.77) in
addition to tumor size greater than 2cm (P <0.0001, HR
1.97, 95% CI 1.65, 2.29) (multivariate analysis with and
without RIP2 expression in Figure 2A and B, respectively).
Other clinical factors such as axillary lymph node involve-
ment, ER status, and age were not independent prognostic
factors for PFS on multivariate analysis although triple-
negative status and younger age (younger than median
age) trended towards worse survival (Figure 2A and B).To further validate RIP2 expression as an independent
prognostic biomarker, we evaluated the prognostic value
of RIP2 expression for only ER-positive patients (n = 465).
High and low RIP2 expression (top versus bottom 30%
of the overall median expression value of the combined
dataset) segregated patients into a high- and low-risk group,
respectively (Figure 2C). There was no direct correlation
between RIP2 expression and tumor size (r = 0.173,
Pearson’s correlation, data not shown). However, within
the larger tumor cohort (size >2 cm), higher RIP2
expression is also prognostic of worse PFS (Figure 2D).
RIP2 expression affects migration and invasion
As tumor metastasis is the main cause of morbidity and
mortality, we investigated the effect of RIP2 expression
on cell migration. Metastasis of breast cancer primarily
occurs through the regional lymphatic system with the
extent of axillary lymph node involvement as a key prog-
nostic factor for the disease. We obtained 17 cases of
stage-III breast cancers with either little or extensive
axillary lymph node involvement, from the University of
Texas Southwestern (UTSW) Tissue Repository. Specif-
ically, we evaluated RIP2 expression by mRNA FISH in
stage-III breast cancer cases with either fewer than four
axillary lymph nodes (N0, N1) or with significant axillary
lymph node involvement (N3 or tumor metastasis in more
than 10 axillary lymph nodes, infraclavicular lymph nodes,
supraclavicular lymph nodes, or clinically detected ipsilat-
eral internal mammary lymph nodes along with other axil-
lary lymph nodes). We found that RIP2 expression
appears to be more prominent in breast cancers that have
significant axillary lymph node spread (Figure 3A,B). The
differential RIP2 expression is not due to triple-negative
status alone (percentage of triple-negative patients in N0/
N1 groups was 33% and in N3 group 25%) and suggests a
specific role for RIP2 in migration.
We interrogated TCGA for stage-III patients with N0
to N1 versus N3 disease and found a similar trend of
higher expression in N3 disease, although the P-value
for the two-sided t-test was not significant (P = 0.825,
see Figure 3C). This needs to be examined further, espe-
cially in a larger dataset of stage-III patients.
Although the public datasets we examined lack ad-
equate annotation for stage determination (only binary
information given for lymph node status), we evaluated
how lymph node status may affect RIP2 expression as a
prognostic indicator (evaluating patients in the top
AB
C D
Figure 2 Multivariate Cox regression analysis using various clinical features with (A) and without (B) RIP2 expression for progression-
free survival (PFS). *P <0.05. Kaplan-Meier estimator using top and bottom 30% RIP2 expression to segregate ER-positive (C) and tumor >2 cm
patient cohorts (D). HR, hazard ratio; n, number of patients.
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Figure 3 RIP2 mRNA expression in primary tumors suggests correlation with extensive axillary lymph node invasion in stage III breast
cancer. (A) RIP2 mRNA fluorescence in situ hybridization (FISH) in primary breast tissue of a representative patient with N3 (top panels) and N0
(bottom panels) breast cancer. Scale bar = 20 μM. (B) Average number of cytoplasmic mRNA foci per 50 cells was used to compare the group of
stage-III patients from the University of Texas Southwestern Medical Center (UTSW) Tissue Repository with extensive (N3) versus limited (N0, N1)
lymph node involvement. Average of three imaging fields per case with error bars representing standard error of the mean (SEM). (C) Relative
RIP2 expression of stage-III patients from The Cancer Genome Atlas (TCGA) with N3 versus N0/N1 disease. Statistics per two-sided Student t-test
for B, C. (D) Kaplan-Meier estimator to evaluate RIP2 expression and lymph node status as prognostic indicator in the combined public expression
array datasets. PFS, progression-free survival.
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high RIP2 expression with node positivity correlated
with significantly worse PFS compared to low RIP2 ex-
pression with node negativity (log-rank P = 0.0042, HR
1.9, 95% CI 1.2, 2.8; Figure 3D).
To further evaluate the correlation of RIP2 expression
with migration or invasion in vitro, we generated RIP2
knockdown using two short-interfering RNAs (siRNAs),
designated si-RIP2 #J and si-RIP2 #D, in the TBNC
cell lines MDA-MB-231, Htb126, and SUM149PT
(Figure 4A, see Methods). Among available TBNC cell
lines, we chose these triple-negative cell lines that
have basal or mesenchymal/stem-like characteristics,
as they represent subtypes of breast cancer with poorprognosis and no available targeted therapies [31].
Both the scratch/wound healing and Matrigel™ transwell
invasion assays showed that decreased RIP2 expression
led to decreased migration. Importantly, reconstituted
RIP2 expression (pcDNA4 Omni-RIP2) largely restored
migratory ability in all three triple-negative breast cancer
cell lines (Figure 4B-E), indicating that the migration defi-
ciency is unlikely to be an off-target effect of our siRNAs
and that RIP2 has a clear role in migration.
As our in silico survival studies indicated a potential
role for RIP2 in ER-positive breast cancer, we then tested
if RIP2 expression affects migratory ability of ER-positive
breast cancer cell lines MCF7, T47D, and HCC1428
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  MDA-MB-231        Htb126           SUM149PT
Figure 4 RIP2 knockdown decreases migration and invasion in triple-negative breast cancer (TNBC) cell lines. (A) Western blot showing
relative protein expressions of RIP2 knockdown (si-RIP2 #J and si-RIP2 #D) and pcDNA4 Omni-tagged RIP2 in three TBNC cell lines. (B) Representative
scratch/wound healing assay images for MDA-MB-231 cells. (C) Quantification of scratch/wound healing assay results for three triple-negative cell lines
and error bars represent standard error of the mean (SEM). Data represent results from three separate experiments. Statistics per Student t-test as
indicated. Scale bar = 100 μM. (D) Representative Matrigel™ invasion assays from MDA-MB-231 cells at 16 hours. (E) Quantification of Matrigel™
invasion assay results for three triple-negative cell lines with error bars representing SEM. Columns represent results from triplicates repeated in three
separate experiments. Statistics per Student t-test.
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and the Matrigel™ invasion (Figure 5C) assays compared
to the TNBC cell lines (Figure 4C,E). Knockdown of
RIP2 decreases the migratory ability of MCF7 and T47D
cells but not HCC1428 cells (Figure 5B,C).
RIP2 expression affects chemosensitivity in vivo and
tumor cell migration
We next investigated the in vivo effect of RIP2 knock-
down using mouse xenograft studies. We injected equal
numbers of short-hairpin (sh) RNA, sh-control and sh-
RIP2 stably expressed in MDA-MB-231 cells (Figure 6A)
into contralateral dorsal flanks of immunodeficient NOD-
SCID mice. As RIP2 knockdown by itself has little effect
on cell growth in vitro (Figure 6B), we used docetaxel (one
of the most common chemotherapies given for breast
cancer) to determine if RIP2 knockdown would chemo-
sensitize tumor cells to docetaxel. RIP2 knockdown cellsshow a significant decrease in tumor mass after docetaxel
treatments compared to non-silencing sh-control MDA-
MB-231 cells injected into contralateral dorsal flanks
(Figure 6C).
We also examined the metastatic potential of sh-
control and shRIP2 MDA-MB-231 cells (these were ori-
ginally derived from a malignant pleural effusion) to the
lungs. Strikingly, after four weekly doses of docetaxel,
lung metastases were noticeably present in all animals
that had only sh-control xenografts (n = 3/3 animals)
(Figure 6D) with large areas where the tumor cells
replaced the lung parenchyma at the time of sacrifice
(2.5 months after xenograft placement). In contrast, no
obvious lung metastases were present in the animals
with sh-RIP2 only xenografts (n = 6/6 animals) (Figure 6E).
RIP2 FISH of the lungs showed that sh-control cells to the
lung retain high RIP2 expression whereas the small








































































































































































  MCF7                 T47D             HCC1428
Figure 5 RIP2 knockdown decreases migration and invasion in certain estrogen receptor (ER)-positive cell lines. (A) Western blot
showing relative protein expressions of RIP2 knockdown (siRIP2 #J) and pcDNA4 Omni-tagged RIP2 in 3 ER-positive breast cancer cell lines.
(B) Quantification of scratch/wound healing assay results for three triple negative cell lines and error bars represent standard error of the mean
(SEM). Data represent results from two separate experiments. Statistics per Student t-test as indicated. (C) Quantification of Matrigel™ invasion
assay results for three ER-positive cell lines with error bars representing SEM. Columns represent results from triplicates repeated in two separate
experiments. Statistics per Student t-test.
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respectively). The significant difference in the presence of
lung metastasis may in part be related to the differences
seen in the primary tumor size in response to chemother-
apy. Additional studies in vivo will be needed to more fully
ascertain the role of RIP2 in metastasis.
RIP2 is an activator of the NF-kappa B and JNK pathways
To understand specific mechanisms underlying the
migration defect seen with RIP2 knockdown in TBNC
cells, we evaluated known pathways downstream of
RIP2, including the NF-kappa B, ERK, JNK, and p-38
pathways [32]. In MDA-MB-231 and Htb126 cells, two
of the cell lines with the greatest migration defects in
our in vitro assays, RIP2 knockdown is associated with
decreased phosphorylation of NF-kappa B and JNK but
not p38 or ERK (Figure 7A). A slight increase in the
phosphorylation of p38 can be observed (Figure 7A).
Both JNK and NF-kappa B are associated with defects in
adhesion [14,15,33]. Focal adhesion kinase (FAK) has
been well-established as a gene significant for cancer
cell migration and metastasis (reviewed in [34]) andis currently being used either as a drug target or as a
biomarker in various solid tumors (see Clinicaltrials.gov).
We therefore evaluated the expression of p-FAK to see if
RIP2 expression correlates with this well-known bio-
marker for migration and metastasis. We found that
although sh-control MDA-MB-231 cells have ample focal
adhesions around the cells, RIP2 knockdown cells have
fewer focal adhesions as reflected by decreased p-FAK
protein (Figure 7A) and less continuous p-FAK staining
around the cells (Figure 7B).
RIP2 kinase activity is necessary for JNK activation but
not NF-kappa B
PP2 is a known small-molecule chemical inhibitor of
RIP2 [35] and the Src family of tyrosine kinases [36]. We
found that at 1 μM PP2 has a noticeable effect on the
amount of RIP2 phosphorylation in MDA-MB-231 cells.
At the same concentration of PP2, there was a correlated
decrease in the amount of phosphorylation of JNK and
FAK but not NF-kappa B (Figure 8A), implicating JNK
activation as a key downstream effector for RIP2-





Figure 6 RIP2 knockdown does not cause decrease in proliferation but does cause decreased tumor growth and lung metastasis
in vivo with docetaxel treatments. (A) Western blot showing relative RIP2 expression in sh-control and sh-RIP2 MDA-MB-231 cells. (B) Relative
proliferation rate of sh-control and sh-RIP2 MDA-MB-231 cells in vitro. (C) Tumor volume at various time points after xenograft placements. Images
are representative of final tumors at 10 weeks for sh-control (top) and sh-RIP2 (bottom). Statistics per Student t-test at final time point recorded.
Representative H&E stains of lung sections at 10 weeks are shown (D and E). Scale bar represents 100 μm. Representative RIP2 fluorescence in situ
hybridization (FISH) images of lung sections are shown in (F) and (G). Red, RIP2 mRNA signal. Blue, 4',6-diamidino-2-phenylindole (DAPI) nuclear
stain. Scale bar represents 25 μm.
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http://breast-cancer-research.com/content/16/2/R28there was a significant decrease in the number of
cells that migrated in the Matrigel™ transwell invasion
assay (Figure 8B,C) when cells were treated with PP2.Discussion
To determine immediate actionable targets from our





































si-control                        si-RIP2
pFAK
t-FAK
Figure 7 RIP2 affects activation of NF-kappaB and JNK pathways. (A) Western blots showing relative expressions of various proteins in
si-control and si-RIP2 cells in 2 triple negative breast cancer cell lines. (B) pFAK immunofluorescence of MDA-MB-231 cells show less abundant
pFAK staining around si-RIP2 cells relative to si-control cells. Scale bar represents 10 μm.
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http://breast-cancer-research.com/content/16/2/R28as a gene important for breast cancer cell metastasis. RIP2
is a kinase with known central roles in inflammation and
immunity. We have demonstrated a novel role for RIP2 in
the metastatic potential of multiple breast cancer cells
with high RIP2 expression both in vitro and in vivo and
shown that it is a target for drug treatment in cancer
therapy.
Although RIP2 is over-expressed more often in
TNBC than other clinical subtypes, we demonstrated
in the present study that RIP2 expression is an inde-
pendent prognostic biomarker. Although high RIP2
expression correlated with triple-negative status, it was
not a mere surrogate of triple-negative status, as high
RIP2 expression also correlated with poor survival in ER-
positive breast cancers and those with tumor size >2 cm.However, although RIP2 may also be a target for other
types of breast cancer (that is, ER-positive), its high
expression within the triple-negative subset identifies
this cohort as the most likely to show immediate
benefit from targeted treatment against RIP2.
Axillary lymph node metastasis in primary breast can-
cers has long been used clinically as a poor prognostic
indicator [37] but there remains controversy about
whether axillary lymph node metastasis reflects lead-time
bias or true tumor biology (that is, metastatic potential or
aggressiveness) [37-39]. Multivariate analysis of our
combined expression array datasets did not reveal lymph
node status to be prognostic for PFS although we found
that RIP2 mRNA expression correlated with extensive




























Figure 8 Chemical inhibition of RIP2 leads to decreased JNK and FAK activation. (A) Western blots showing relative expressions of various
proteins in MDA-MB-231 cells treated with indicated doses of PP2. (B) Representative Matrigel™ invasion assays from MDA-MB-231 cells at
16 hours when treated with indicated doses of PP2. (C) Quantification of Matrigel™ invasion assay results for MDA-MB-231 cells treated with PP2
with error bars representing standard error of the mean (SEM). Columns represent results from two separate experiments done in triplicates.
Statistics per Student t-test.
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http://breast-cancer-research.com/content/16/2/R28This suggests that a combination of lymph node status
and RIP2 expression may prove to be of prognostic utility
in the clinical setting. However, studies involving larger
samples are needed to elucidate the role of RIP2 in axillary
lymph node spread.
Here we provided in vitro evidence for the role of
RIP2 in migration and invasion in TNBC and selected
ER-positive breast cancers. The effect of RIP2 knock-
down in ER-positive cell lines, although significant for
MCF7 and T47D, was modest compared to the effect of
RIP2 knockdown in the triple-negative cell lines. TNBC
and ER-positive breast cancers have significantly differ-
ent clinical courses, with TNBC generally being more
likely to relapse, metastasize, and be resistant to treat-
ment [40]. Expression array analysis of TBNC has re-
vealed multiple subtypes, each with various potential
targets [31]. Recent large clinical trials have failed to val-
idate the clinical efficacy of various targets deemed to be
important for subsets of TNBC (examples include ini-
parib against poly-ADP ribose polymerase [41] and bev-
acizumab against vascular endothelial growth factor
receptor [42]). There is clearly an unmet need for add-
itional therapeutic targets. As high expression of RIP2 is
found in approximately 80 to 90% of TNBCs and ap-
proximately 50% of ER-positive breast cancers, RIP2 kin-
ase is an attractive novel therapeutic target for the
majority of TNBC and selected ER-positive breast can-
cers that have upregulated RIP2.
We have found that RIP2 knockdown correlates with
decreased phosphorylation of JNK and NF-kappa B in
TNBC. Both of these pathways have well-known roles incancer progression. In our current studies, we observed
a slight increase in the phosphorylation of p38, suggest-
ing a potential compensatory effect. JNK and p38 inte-
grate signals involved in proliferation, differentiation,
survival and migration (reviewed in [43]). Conversely,
NF-kappa B activation by RIP2 has been shown to be
secondary to interactions from a multimeric complex of
proteins and not directly from RIP2 kinase activity [44].
Our results suggest that although RIP2 may be a crucial
member of the complex that controls NF-kappaB activa-
tion, its kinase activity is not necessary for NF-kappa B
activation. However, the kinase activity of RIP2 appears
to be important for the activation of JNK. Further exper-
iments on the mechanism of RIP2 activation of JNK and
NF-kappa B, along with potential compensatory alter-
ations in other pathways are necessary.
Conclusions
We previously found that RIP2 knockdown increases
chemosensitivity [7]. Here, we demonstrated that RIP2
has a role in facilitating metastasis and is an independ-
ent prognostic marker for breast cancer. Its association
with human breast tumors and patient outcome war-
rants further investigation. We have identified RIP2 as a
gene that is upregulated in the majority of TBNCs and
likely contributes to the metastatic process.
Abbreviations
ATCC: American Type Culture Collection; ER: estrogen receptor;
ERK: extracellular signal-regulated kinase; FAK: Focal adhesion kinase;
FISH: fluorescence in situ hybridization; GAPDH: glyceraldehyde-3-phosphate
dehydrogenase; GEO: Gene Expression Omnibus; H&E: Hematoxylin and
Singel et al. Breast Cancer Research 2014, 16:R28 Page 13 of 14
http://breast-cancer-research.com/content/16/2/R28eosin; IP: intraperitoneal; JNK: c-Jun N-terminal kinase; p-38: mitogen-
activated protein kinase; PFS: progression-free survival (the time elapsed
between treatment initiation and tumor progression or death from any
cause with censoring of patients who are lost to follow-up); PP2: 3-(4-
chlorophenyl) 1-(1,1-dimethylethyl)-1H-pyrazolo(3,4-d)pyrimidin-4-amine;
RIP: Receptor-interacting protein kinase 2; SEM: standard error of the mean;
shRNA: short-hairpin RNA; siRNA: small-interfering RNA; TCGA: The Cancer
Genome Atlas; TNBC: triple-negative breast cancer; TNF: tumor necrosis
factor; UTSW: The University of Texas Southwestern Medical Center in Dallas.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
SMS: conception and design, development of methodology, acquisition of
data, analysis and interpretation of data, writing of the manuscript. CC:
development of methodology, acquisition of data, manuscript revision. KB:
development of methodology, acquisition of data, manuscript revision. GJ:
acquisition of data, manuscript revision. SLB: acquisition of data, manuscript
revision. GFL: development of methodology, acquisition of data, manuscript
revision. WEW: analysis and interpretation of data, manuscript revision. JWS:
analysis and interpretation of data, manuscript revision. All authors read and
approved the final manuscript.
Acknowledgements
We would like to thank D Abbott (Department of Pathology, Case Western
Reserve University, Cleveland, OH) for plasmids; M White (Department of Cell
Biology, Department of Cell Biology, University of Texas Southwestern
Medical School, Dallas, TX) for tissue culture cells, and breast cancer tissue
from the University of Texas Southwestern Tissue Management Shared
Resources. The project was supported by Simmons Cancer Center Support
Grant (5P30 CA 142543-03), T32CA136515 from the National Cancer Institute
and Susan G Komen Foundation Postdoctoral Fellowship for SMS, and The
Southland Financial Corporation Distinguished Chair in Geriatric Research for
JWS. This work was performed in laboratories constructed with support from
National Institute of Health grant C06 RR30414.
Author details
1Departments of Cell Biology, University of Texas Southwestern Medical
Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9039, USA.
2Departments of Internal Medicine, University of Texas Southwestern Medical
Center, Dallas, TX, USA.
Received: 25 June 2013 Accepted: 6 March 2014
Published: 19 March 2014
References
1. Lupfer C, Thomas PG, Anand PK, Vogel P, Milasta S, Martinez J, Huang G,
Green M, Kundu M, Chi H, Xavier RJ, Green DR, Lamkanfi M, Dinarello CA,
Doherty PC, Kanneganti TD: Receptor interacting protein kinase
2-mediated mitophagy regulates inflammasome activation during virus
infection. Nat Immunol 2013, 14:480–488.
2. Magalhaes JG, Lee J, Geddes K, Rubino S, Philpott DJ, Girardin SE: Essential
role of Rip2 in the modulation of innate and adaptive immunity
triggered by Nod1 and Nod2 ligands. Eur J Immunol 2011, 41:1445–1455.
3. Tigno-Aranjuez JT, Asara JM, Abbott DW: Inhibition of RIP2’s tyrosine
kinase activity limits NOD2-driven cytokine responses. Genes Dev 2010,
24:2666–2677.
4. Inohara N, del Peso L, Koseki T, Chen S, Nunez G: RICK, a novel protein
kinase containing a caspase recruitment domain, interacts with
CLARP and regulates CD95-mediated apoptosis. J Biol Chem 1998,
273:12296–12300.
5. McCarthy JV, Ni J, Dixit VM: RIP2 is a novel NF-kappaB-activating and cell
death-inducing kinase. J Biol Chem 1998, 273:16968–16975.
6. Thome M, Hofmann K, Burns K, Martinon F, Bodmer JL, Mattmann C,
Tschopp J: Identification of CARDIAK, a RIP-like kinase that associates
with caspase-1. Curr Biol 1998, 8:885–888.
7. Singel SM, Cornelius C, Batten K, Fasciani G, Wright WE, Lum L, Shay JW: A
Targeted RNAi screen of the breast cancer genome identifies KIF14
and TLN1 as genes that modulate docetaxel chemosensitivity in
triple-negative breast cancer. Clin Cancer Res 2013, 19:2061–2070.8. Navas TA, Baldwin DT, Stewart TA: RIP2 is a Raf1-activated
mitogen-activated protein kinase kinase. J Biol Chem 1999,
274:33684–33690.
9. Jacquet S, Nishino Y, Kumphune S, Sicard P, Clark JE, Kobayashi KS, Flavell
RA, Eickhoff J, Cotten M, Marber MS: The role of RIP2 in p38 MAPK
activation in the stressed heart. J Biol Chem 2008, 283:11964–11971.
10. Helbig G, Christopherson KW 2nd, Bhat-Nakshatri P, Kumar S, Kishimoto H,
Miller KD, Broxmeyer HE, Nakshatri H: NF-kappaB promotes breast cancer
cell migration and metastasis by inducing the expression of the
chemokine receptor CXCR4. J Biol Chem 2003, 278:21631–21638.
11. Kang H, Lee M, Choi KC, Shin DM, Ko J, Jang SW: N-(4-hydroxyphenyl)
retinamide inhibits breast cancer cell invasion through suppressing
NF-KB activation and inhibiting matrix metalloproteinase-9 expression.
J Cell Biochem 2012, 113:2845–2855.
12. Moreau M, Mourah S, Dosquet C: beta-Catenin and NF-kappaB cooperate
to regulate the uPA/uPAR system in cancer cells. Int J Cancer 2011,
128:1280–1292.
13. Hartman ZC, Poage GM, den Hollander P, Tsimelzon A, Hill J, Panupinthu N,
Zhang Y, Mazumdar A, Hilsenbeck SG, Mills GB, Brown PH: Growth of
triple-negative breast cancer cells relies upon coordinate autocrine
expression of the proinflammatory cytokines IL-6 and IL-8. Cancer Res
2013, 73:3470–3480.
14. Huang C, Rajfur Z, Borchers C, Schaller MD, Jacobson K: JNK
phosphorylates paxillin and regulates cell migration. Nature 2003,
424:219–223.
15. Lee MH, Koria P, Qu J, Andreadis ST: JNK phosphorylates beta-catenin and
regulates adherens junctions. FASEB J 2009, 23:3874–3883.
16. Kawahara E, Maenaka S, Shimada E, Nishimura Y, Sakurai H: Dynamic
regulation of extracellular signal-regulated kinase (ERK) by protein
phosphatase 2A regulatory subunit B56gamma1 in nuclei induces cell
migration. PLoS One 2013, 8:e63729.
17. Moore HM, Gonzalez ME, Toy KA, Cimino-Mathews A, Argani P, Kleer CG:
EZH2 inhibition decreases p38 signaling and suppresses breast cancer
motility and metastasis. Breast Cancer Res Treat 2013, 138:741–752.
18. The Cancer Genome Atlas Data Portal. https://tcga-data.nci.nih.gov/tcga/.
19. Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, Pawitan Y,
Hall P, Klaar S, Liu ET, Bergh J: An expression signature for p53
status in human breast cancer predicts mutation status,
transcriptional effects, and patient survival. Proc Natl Acad Sci USA
2005, 102:13550–13555.
20. Loi S, Haibe-Kains B, Desmedt C, Lallemand F, Tutt AM, Gillet C, Ellis P,
Harris A, Bergh J, Foekens JA, Klijn JG, Larsimont D, Buyse M, Bontempi G,
Delorenzi M, Piccart MJ, Sotiriou C: Definition of clinically distinct
molecular subtypes in estrogen receptor-positive breast carcinomas
through genomic grade. J Clin Oncol 2007, 25:1239–1246.
21. van de Vijver MJ, He YD, van’t Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber
GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas
A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend
SH, Bernards R: A gene-expression signature as a predictor of survival in
breast cancer. N Engl J Med 2002, 347:1999–2009.
22. Gene Expression Omnibus (GEO) public functional genomics data
repository. www.ncbi.nlm.nih.gov/geo/.
23. Pawitan Y, Bjohle J, Amler L, Borg AL, Egyhazi S, Hall P, Han X, Holmberg L,
Huang F, Klaar S, Liu ET, Miller L, Nordgren H, Ploner A, Sandelin K, Shaw
PM, Smeds J, Skoog L, Wedren S, Bergh J: Gene expression profiling
spares early breast cancer patients from adjuvant therapy: derived and
validated in two population-based cohorts. Breast Cancer Res 2005,
7:R953–R964.
24. Desmedt C, Piette F, Loi S, Wang Y, Lallemand F, Haibe-Kains B, Viale G,
Delorenzi M, Zhang Y, d’Assignies MS, Bergh J, Lidereau R, Ellis P, Harris AL,
Klijn JG, Foekens JA, Cardoso F, Piccart MJ, Buyse M, Sotiriou C: Strong time
dependence of the 76-gene prognostic signature for node-negative
breast cancer patients in the TRANSBIG multicenter independent
validation series. Clin Cancer Res 2007, 13:3207–3214.
25. Computational Cancer Biologty, Division of Molecular Carcinogenesis,
Netherlands Cancer Institute Data portal. http://bioinformatics.nki.nl/data.php.
26. A subtyping tool for triple-negative breast cancer. https://cbc.mc.
vanderbilt.edu/tnbc/.
27. Abbott DW, Wilkins A, Asara JM, Cantley LC: The Crohn’s disease protein,
NOD2, requires RIP2 in order to induce ubiquitinylation of a novel site
on NEMO. Curr Biol 2004, 14:2217–2227.
Singel et al. Breast Cancer Research 2014, 16:R28 Page 14 of 14
http://breast-cancer-research.com/content/16/2/R2828. Gruneberg U, Neef R, Li X, Chan EH, Chalamalasetty RB, Nigg EA, Barr FA:
KIF14 and citron kinase act together to promote efficient cytokinesis.
J Cell Biol 2006, 172:363–372.
29. Ewing RM, Chu P, Elisma F, Li H, Taylor P, Climie S, McBroom-Cerajewski L,
Robinson MD, O’Connor L, Li M, Taylor R, Dharsee M, Ho Y, Heilbut A,
Moore L, Zhang S, Ornatsky O, Bukhman YV, Ethier M, Sheng Y, Vasilescu J,
Abu-Farha M, Lambert JP, Duewel HS, Stewart II, Kuehl B, Hogyue K, Colwill
K, Gladwish K, Muskat B: Large-scale mapping of human protein-protein
interactions by mass spectrometry. Mol Syst Biol 2007, 3:89.
30. Network CGA: Comprehensive molecular portraits of human breast
tumours. Nature 2012, 490:61–70.
31. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y,
Pietenpol JA: Identification of human triple-negative breast cancer
subtypes and preclinical models for selection of targeted therapies.
J Clin Invest 2011, 121:2750–2767.
32. Zhang D, Lin J, Han J: Receptor-interacting protein (RIP) kinase family.
Cell Mol Immunol 2010, 7:243–249.
33. Ko BS, Chang TC, Chen CH, Liu CC, Kuo CC, Hsu C, Shen YC, Shen TL,
Golubovskaya VM, Chang CC, Shyue SK, Liou JY: Bortezomib suppresses
focal adhesion kinase expression via interrupting nuclear factor-kappa B.
Life Sci 2010, 86:199–206.
34. Golubovskaya VM, Cance W: Focal adhesion kinase and p53 signal
transduction pathways in cancer. Front Biosci 2010, 15:901–912.
35. Windheim M, Lang C, Peggie M, Plater LA, Cohen P: Molecular
mechanisms involved in the regulation of cytokine production by
muramyl dipeptide. Biochem J 2007, 404:179–190.
36. Hanke JH, Gardner JP, Dow RL, Changelian PS, Brissette WH, Weringer EJ,
Pollok BA, Connelly PA: Discovery of a novel, potent, and Src family-
selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T
cell activation. J Biol Chem 1996, 271:695–701.
37. Jatoi I, Hilsenbeck SG, Clark GM, Osborne CK: Significance of axillary
lymph node metastasis in primary breast cancer. J Clin Oncol 1999,
17:2334–2340.
38. van der Heiden-van der Loo M, Schaapveld M, Ho VK, Siesling S, Rutgers EJ,
Peeters PH: Outcomes of a population-based series of early breast cancer
patients with micrometastases and isolated tumour cells in axillary
lymph nodes. Ann Oncol 2013, 24:2794–2801.
39. Chang MC, Escallon JM, Colgan TJ: Prognostic significance of a positive
axillary lymph node fine-needle aspirate in patients with invasive breast
carcinoma. Cancer cytopathology 2013, 122:138–144.
40. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA,
Rawlinson E, Sun P, Narod SA: Triple-negative breast cancer: clinical
features and patterns of recurrence. Clin Cancer Res 2007, 13:4429–4434.
41. O’Shaughnessy J, Schwartzberg L, Danso M, Rugo H, Miller K, Yardley D,
Carlson R, Finn R, Charpentier E, Freese M, Gupta S, Blackwood-Chirchir A,
Winer EP: A randomized phase III study of iniparib (BSI-201) in
combination with gemcitabine/carboplatin (G/C) in metastatic
triple-negative breast cancer (TNBC). J Clin Oncol 2011,
29: suppl; abstr 1007.
42. Cameron D, Brown J, Dent R, Jackisch C, Mackey J, Pivot X, Steger GG,
Suter TM, Toi M, Parmar M, Laeufle R, Im YH, Romieu G, Harvey V, Lipatov O,
Pienkowski T, Cottu P, Chan A, Im SA, Hall PS, Bubuteishvili-Pacaud L,
Henschel V, Deurloo RJ, Pallaud C, Bell R: Adjuvant bevacizumab-
containing therapy in triple-negative breast cancer (BEATRICE): primary
results of a randomised, phase 3 trial. Lancet Oncol 2013, 14:933–942.
43. Wagner EF, Nebreda AR: Signal integration by JNK and p38 MAPK
pathways in cancer development. Nat Rev Cancer 2009, 9:537–549.
44. Conde C, Rambout X, Lebrun M, Lecat A, Di Valentin E, Dequiedt F,
Piette J, Gloire G, Legrand S: The inositol phosphatase SHIP-1 inhibits
NOD2-induced NF-kappaB activation by disturbing the interaction of
XIAP with RIP2. PLoS One 2012, 7:e41005.
doi:10.1186/bcr3629
Cite this article as: Singel et al.: Receptor-interacting protein kinase 2
promotes triple-negative breast cancer cell migration and invasion via
activation of nuclear factor-kappaB and c-Jun N-terminal kinase
pathways. Breast Cancer Research 2014 16:R28.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
